Pelargonium (Umckaloabo) for Respiratory Health

Research suggests that Pelargonium sidoides extract (commonly sold as Umckaloabo or EPs 7630) may offer some benefit for acute respiratory tract infections, including bronchitis, sinusitis, and the common cold, with one randomized controlled trial in over 200 patients reporting meaningful symptom reduction and early onset of relief within two days of treatment. A 2014 scientific review supports a plausible biological rationale, indicating that laboratory studies point to indirect antimicrobial effects — such as blocking pathogen adhesion and stimulating the body's immune defenses — rather than direct pathogen killing. However, a Cochrane meta-analysis pooling data from eight trials found mixed results depending on the form of the extract, with the liquid formulation showing more consistent effects than tablets, and the overall quality of evidence was rated low to very low, with concerns about publication bias and methodology. Studies indicate the extract is generally well tolerated with no serious adverse events reported in these trials, though side effects were more common than with placebo, and researchers across all study types emphasize that further high-quality research is needed before firm conclusions can be drawn.